St. John's Wort Extract LI 160 for the Treatment of Atypical Depression

• Status: Completed
• Trial end date: 2004-11-01
• Target enrollment: 0
• Participant gender: All

Summary

The aim of tis study is to assess the efficacy and safety of Jarsin® 300 mg as an acute treatment in mild to moderate depression with atypical features.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Cassella-med GmbH & Co. KG

Criteria

Main Inclusion Criteria:

• Mild to moderate depression (ICD-10 F32.0, F32.1) with atypical features according to DSM-IV, lasting at least 3 months

• Female and male Caucasians aged 18 to 70 years

• At least one of HAMD-28 scale items 22-26 scores >1